As many companies are trying to develop liquid biopsy for diagnosing and preventing cancer development, the San Diego-based genome sequencing company Illumina has also joined this group.
Illumina has announced that it will create a new company called "Grail" for developing liquid biopsy for cancer diagnosis. It will develop an exclusive blood test to identify early-stage cancers in people with no symptoms of the disease.
California-Based Company Launches “Liquid Biopsy” to Detect Cancer DNA in Healthy People
Pathway Genomics screening test will look at 96 genetic markers associated with major cancer types such as breast, ovarian, lung, colon and melanoma.
Advertisement
‘Illumina, a genome sequencing company, is launching a new company that will develop and market a test to detect genetic evidence of cancer in the blood.’
Tweet it Now
Grail's test will use Illumina's DNA sequencing technology to scan for bits of cancer genes originating in tumors and circulating in the bloodstream. The hope is to detect many types of newly forming tumors, which could be treated at an earlier stage to increase the chances of survival.
Illumina Chief Executive, Jay Flatley, who will serve as Chairman of Grail, said, "We hope today is a turning point in the war on cancer. By enabling the early detection of cancer in asymptomatic individuals through a simple blood screen, we aim to massively decrease cancer mortality by detecting the disease at a curable stage."
Source: Medindia
Source: Medindia
New Blood Test May Detect Success of Cancer Treatments and Relapse in Cancer Patients
World's first breakthrough discovery on detecting success of cancer treatment and cancer relapse in patients could fast-track existing cancer treatments.
Advertisement
 Pancreas Cancer Liquid Biopsy Flows from Blood-Borne PacketsConducting biopsies during treatment would more closely monitor therapy success or failure and help researchers better understand how the cancer genome evolves. | Advertisement
|
Nanotech Sensor That Measures MicroRNAs in Blood Could Speed Cancer Detection
The ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies for the prognosis and treatment of pancreatic and other cancers.
Advertisement
Recommended Reading
Latest Corporate News
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.